Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. O‘Donnell, R. Swarnakar, L. Yashina, P. Nikolova, R. Marinov, P. Waghray, V. Melnik, Z. Lazic, A. Penev, K. Dimakou, M. Mitic-Milikic, I. Kline, G. Tino, D. Bilton, R. Gupta (Monmouth Junction, United States Of America). A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic pseudomonas aeruginosa lung infection. Eur Respir J 2009; 34: Suppl. 53, 1361

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007 A comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a double-blind, efficacy and safety study in Chinese adults with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006 Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006 A single centre double-blind placebo controlled pilot study into the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004 Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 An open label randomized controlled trial comparing nebulized amphotericin B with oral itraconazole in patients with pulmonary aspergilloma Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 A randomized trial of the effectiveness of nebulized therapy with epinephrine compared with salbutamol in the treatment of acute viral bronchiolitis Source: Eur Respir J 2005; 26: Suppl. 49, 127s Year: 2005 Comparison of oral prednisolone and nebulized budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 214s Year: 2001 Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies Source: Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020 Year: 2020 A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Randomized controlled trial of nebulized budesonide suspension in acute severe exacerbation of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007 Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe COPD Source: Annual Congress 2011 - Role of infection in exacerbations of COPD Year: 2011 Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007 A randomized, placebo-controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease(COPD) Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003 Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the  BEST-2 trial Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014